In-Depth Competitive Landscape Assessment of the Cancer Immunotherapy Market Place.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c50129) has announced the addition of Triple Analysis: Apoptosis apoptosis or programmed cell death Mechanism that allows cells to self-destruct when stimulated by the appropriate trigger. It may be initiated when a cell is no longer needed, when a cell becomes a threat to the organism's health, or for other reasons. Agents, Antibodies and Vaccines in Oncology to their offering. In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Apoptopic agents, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 350+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia leukemia (l  kē`mēə), cancerous disorder of the blood-forming tissues (bone marrow, lymphatics, liver, spleen) characterized by excessive production of immature or mature , lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. ,
lymphoma and prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . A thorough target analysis of drugs in
development reveals more than 130 candidate targets for triggering
apoptosis in cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping.See also: Cancer . Competitive forces are reviewed, showing market leaders, active players and changes in the competitive landscape. There are only one big pharma company represented among the top 10 players in apoptopic drug development in oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is principal example of a further step in big pharma strategy to augment their internal research and development efforts with high-potential, externally sourced product candidates and technologies. Apoptopic Agents Highlights - In-depth competitive landscape assessment of the apoptopic market in oncology - Thorough review of utilized targets in apoptopic drug development - Thorough review of approved drugs - Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls - Among the targeted therapies for cancer, immunotherapy is probably the most versatile treatment strategy for the eradication of tumors, metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. spread or not. Main strategies of cancer immunotherapy Cancer immunotherapy is the use of the immune system to reject cancer. The main premise is stimulating the patient's immune system to attack the malignant tumor cells that are responsible for the disease. aim at exploiting the therapeutic potential of tumor-specific antibodies and cellular immune effector effector /ef·fec·tor/ (e-fek´ter) 1. an agent that mediates a specific effect. 2. an organ that produces an effect in response to nerve stimulation. mechanisms (vaccines). Immunotherapy in Highlights - In-depth competitive landscape assessment of the cancer immunotherapy market place; Including more than 200 immunotherapy drugs and pharmaceutical companies - Thorough review of tumor antigen tumor antigen n. Any of several antigens present in tumors induced by certain types of adenoviruses and papovaviruses or in cells transformed in vitro by those viruses. Also called neoantigen, T antigen. discovery, immunomodulating strategies and adjuvants - Thorough review of antibody and vaccine delivery and technologies surrounding it - The next generation - Progress analysis of six major cancer vaccine The term cancer vaccine is often used to describe a process whereby a person's immune system is coaxed into recognizing and destroying malignant cells without harming normal cells. indications and late stage antibody development projects, including players, drugs, clinical progress and pitfalls Topics Covered 1 Executive Summary 2 Table of Contents 3 Methodology 4 Introduction to Apoptosis in Oncology 5 Apoptosis Competitive Landscape in Oncology 6 Approved Apoptopic Cancer Drugs: Performance 7 Target Analysis in Apoptosis 8 Apoptopic Drugs in Development: By Major Indications 9 Immunotherapy in Oncology 10 Competitive Landscape in Cancer Vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine 11 Antibody Deals on the Rise 12 Tumor Antigens 13 Immunomodulators & Adjuvants in Cancer Vaccines 14 Cancer Vaccine Delivery 15 New Approaches in Antibody Delivery and Design - The Next Generation 16 Cancer Vaccines in Development: By Major Indications 17 Antibodies in Clinical Development 18 Disclaimer 19 Company Index 20 Drug Index 21 List of Boxes 22 List of Figures 23 List of Tables For more information visit http://www.researchandmarkets.com/reports/c50129 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion